Beruflich Dokumente
Kultur Dokumente
Ribeiro Preto
2011
RESUMO
SIMES, A. C. V. Avaliao do efeito neuroprotetor do canabidiol
em mitocndrias isoladas de crtex cerebral de ratos. 2011.
Dissertao (Mestrado) - Faculdade de Cincias Farmacuticas de
Ribeiro Preto, Universidade de So Paulo, Ribeiro Preto, 2011.
canabidiol;
neuroproteo;
doenas
1 INTRODUO
1.1
locomotora,
alimentos
memria,
reaes
percepo
inflamatrias
da
dor,
(GRUNDY;
ingesto
de
RABUFFETTI;
sua
BELTRAMO,
atividade
2001;
neurotransmissores
farmacolgica
ZUARDI,
2008).
(colinrgicos,
(GRUNDY;
Enquanto
adrenrgicos
RABUFFETTI;
outros
e
sistemas
dopaminrgicos)
seu
elevado
potencial
antioxidante
teraputico
tm
sido
associados
ao
estresse
oxidativo
foram
avaliados
em
modelos
animais
da
doena
de
Parkinson
Tornam-se
necessrios
estudos
adicionais
no
para
morrem
cada
ano
em
conseqncia
de
distrbios
(DP)
perda
se
principalmente
nos
neurnios
por
dificuldades
na
coordenao
dos
movimentos
(PRZEDBORSKI;
VILA;
JACKSON-LEW IS,
2003).
crebro
PETROZZI
et
al.,
2007).
Estudos
relativos
doenas
apoptose
(ANDERSEN,
SCHW ARZENBACHER;
LIPTON,
2004;
2004;
BOSSY-W ETZEL;
CALABRESE
et
al.,
2005;
nas desordens
reativas
de
oxignio
(ERO)
na
clula,
formadas
designado
estresse
oxidativo
(HALLIW ELL;
GUTTERIDGE,
2006).
As
leses
neuronais
observadas
na
isquemia
doenas,
incluindo
neoplasias,
doenas
auto-imunes
suficiente
para
formar
os
circuitos
entre
as
clulas
sintomas da
a morte
dos neurnios
da
diferem
em
condies
fisiolgicas
em
condies
VERCESI
et
al.,
2006).
As
alteraes
que
ocorrem
na
ciclosporina
(CsA),
que
atuam
diretamente
na
mitocndria
TPMM
um fenmeno
bem documentado,
mediado
pela
fatores
pr-apoptticos,
como
citocromo
c,
do
espao
com
particularmente
da
base
no
TPMM
no
importante
papel
desenvolvimento
da
e
mitocndria
progresso
das
2 CONCLUSES
da
apoptose,
eventos
via mitocondrial de
implicados
na
neurodegenerao;
funo
mitocondrial,
como
demonstrado
pelos
10
REFERNCI AS
BATANDIER, C.;
FONTAINE, E.;
KERIEL, C.;
LEVERVE, X. M.
Determination of mitochondrial reactive oxygen species: methodological
aspects. Journal of Cellular and Molecular Medicine. Malden, v. 6, n.
2, p. 175-187, 2002.
11
CONSROE, P.; LAGUNA, J.; ALLENDER, J.; SNIDER, S.; STERN, L.;
SANDYK, R.; KENNEDY, K.; SCHRAM, K. Controlled clinical trial of
cannabidiol in Huntington's disease. Pharmacology Biochemistr y And
Behavior. Oxford, v. 40, n. 3, p. 701-8, 1991.
COSTA, B.;
TROVATO, A. E.;
COMELLI, F.;
GIAGNONI, G.;
COLLEONI, M. The non-psychoactive cannabis constituent cannabidiol
is an orally effective therapeutic agent in rat chronic inflammatory and
neuropathic pain. European Journal of Pharmacology. Amsterdam, v.
556, n. 1-3, p. 75-83, 2007.
12
DIRIKOC, S.;
PRIOLA, S. A.;
MARELLA, M.;
ZSURGER, N.;
CHABRY, J. Nonpsychoactive cannabidiol prevents prion accumulation
and protects neurons against prion toxicity. Journal of Neuroscience.
W ashington, v. 27, n. 36, p. 9537-9544, 2007.
DURST, R.;
DANENBERG, H.;
GALILEE, R.;
MECHOULAM, R.;
BEERI, R.; MEIR, K.; GRAD, E.; AXELROD, E.; PUGATCH, T.;
LOTAN, C. Cardioprotective effect of cannabidiol, a nonpsychoactive
cannabis constituent, in ischemic reperfusion injury. Journal of the
American College of Cardiology. New York, v. 49, n. 9, p. 186a-186a,
2007.
13
HAMPSON, A. J.;
GRIMALDI, M.;
AXELROD, J.;
W INK, D.
Cannabidiol and (-)Delta(9)-tetrahydrocannabinol are neuroprotective
antioxidants. Proceedings of the National Academ y of Sciences of
the United States of America. W ashington, v. 95, n. 14, p. 8268-8273,
1998.
HUNTER, D. R.;
HAW ORTH, R. A. The Ca2+-induced membrane
transition in mitochondria. I. The protective mechanisms. Archives Of
Biochemistr y And Biophysics . New York, v. 195, n. 2, p. 453-9,
1979.
14
MANSSON, R.;
HANSSON, M. J.;
MOROTA, S.;
UCHINO, H.;
EKDAHL, C. T.; ELMER, E. Re-evaluation of mitochondrial permeability
transition as a primary neuroprotective target of minocycline.
Neurobiology Of Disease . San Diego, v. 25, n. 1, p. 198-205, 2007.
MISHIMA, K.; HAYAKAW A, K.; ABE, K.; IKEDA, T.; EGASHIRA, N.;
IW ASAKI, K.; FUJIW ARA, M. Cannabidiol prevents cerebral infarction
via
a
serotonergic
5-hydroxytryptamine(1A)
receptor-dependent
mechanism. Stroke. Philadelphia, v. 36, n. 5, p. 1071-1076, 2005.
MOREL, I.;
LESCOAT, G.;
COGREL, P.;
SERGENT, O.;
PASDELOUP, N.;
BRISSOT, P.;
CILLARD, P.;
CILLARD, J.
Antioxidant and Iron-Chelating Activities of the Flavonoids Catechin,
Quercetin and Diosmetin on Iron-Loaded Rat Hepatocyte Cultures.
Biochemical Pharmacology. Oxford, v. 45, n. 1, p. 13-19, 1993.
15
MOROTA, S.;
MANSSON, R.;
HANSSON, M. J.;
KASUYA, K.;
SHIMAZU, M.; HASEGAW A, E.; YANAGI, S.; OMI, A.; UCHINO, H.;
ELMER, E. Evaluation of putative inhibitors of mitochondrial
permeability transition for brain disorders--specificity vs. toxicity.
Experimental Neurology. San Diego, v. 218, n. 2, p. 353-62, 2009a.
MOROTA, S.;
MANSSON, R.;
HANSSON, M. J.;
KASUYA, K.;
SHIMAZU, M.; HASEGAW A, E.; YANAGI, S.; OMI, A.; UCHINO, H.;
ELMER, E. Evaluation of putative inhibitors of mitochondrial
permeability transition for brain disorders - Specificity vs. toxicity.
Experimental Neurology. San Diego, v. 218, n. 2, p. 353-362, 2009b.
NORENBERG, M. D.;
RAO, K. V. The mitochondrial permeability
transition in neurologic disease. Neurochemistr y International .
Oxford, v. 50, n. 7-8, p. 983-97, 2007.
NUNOMURA, A.; HONDA, K.; TAKEDA, A.; HIRAI, K.; ZHU, X.;
SMITH, M. A.;
PERRY, G. Oxidative damage to RNA in
neurodegenerative
diseases.
Journal
Of
Biomedicine
And
Biotechnology , New York, v. 2006, n. 3, p. 82323, 2006.
PALIW AL, R.; RAI, S.; VAIDYA, B.; MAHOR, S.; GUPTA, P. N.;
RAW AT, A.;
VYAS, S. P. Cell-selective mitochondrial targeting:
progress in mitochondrial medicine. Current Drug Deliver y, Oak Park,
v. 4, n. 3, p. 211-24, 2007.
PETROZZI, L.;
RICCI, G.;
GIGLIOLI, N. J.;
SICILIANO, G.;
MANCUSO, M. Mitochondria and neurodegeneration. Bioscience
Reports, London, v. 27, n. 1-3, p. 87-104, 2007.
POPE, C.;
MECHOULAM, R.;
PARSONS, L. Endocannabinoid
signaling in neurotoxicity and neuroprotection. Neurotoxicology.
Amsterdam v. 31, n. 5, p. 562-71, 2010.
PRZEDBORSKI, S.;
JACKSON-LEW IS, V.;
DJALDETTI, R.;
LIBERATORE, G.;
VILA, M.;
VUKOSAVIC, S.;
ALMER, G. The
parkinsonian toxin MPTP: action and mechanism. Restorative
Neurology And Neuroscience. Amsterdam v. 16, n. 2, p. 135-142,
2000.
16
PRZEDBORSKI,
S.;
VILA,
M.;
JACKSON-LEW IS,
V.
Neurodegeneration: what is it and where are we? Journal Of Clinical
Investigation. Ann Arbor, v. 111, n. 1, p. 3-10, 2003.
ROBBERECHT, W.;
VAN DEN BOSCH, L. The pathogenesis of
amyotrophic
lateral
sclerosis.
Neuroscience
Research
Communications. Malden, v. 23, n. 2, p. 67-75, 1998.
G.
A
of
v.
17
VERCESI, A. E.;
KOW ALTOW SKI, A. J.;
OLIVEIRA, H. C. F.;
CASTILHO, R. F. Mitochondrial Ca2+ transport, permeability transition
and oxidative stress in cell death: implications in cardiotoxicity,
neurodegeneration and dyslipidemias. Frontiers in Bioscience. New
York, v. 11, p. 2554-2564, 2006.
YAN, N.;
SHI, Y. G. Mechanisms of apoptosis through structural
biology. Annual Review of Cell and Developmental Biology. Palo
Alto, v. 21, p. 35-56, 2005.
ZAIDAN, E.;
NILSSON, M.;
SIMS, N. R. Increased mitochondrial
permeability
in
response
to
intrastriatal
N-methyl-D-aspartate:
Detection based on accumulation of radiolabel from [H-3]deoxyglucose.
Neurochemical Research. New York, v. 29, n. 3, p. 609-616, 2004.
18